Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

Autor: Adema, V, Kerr, CM, Walter, W, Hutter, S, Nagata, Y, Awada, H, Kongkiatkamon, S, Snider, CA, Co, M, Magdalena, R, Durmaz, A, Meggendorfer, M, Nazha, A, Scott, J, Carraway, HE, Sekeres, MA, Francesc Solé, Haferlach, T, Visconte, V, Maciejewski, JP

Publikováno v: Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::f22a405d64cf61cc26ff7937d574dd17
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4860

Addition of histone deacetylase inhibitors in combination therapy.

Autor: Carraway HE, Gore SD, Carraway, Hetty E, Gore, Steven D

Publikováno v: Journal of Clinical Oncology; 5/20/2007, Vol. 25 Issue 15, p1955-1956, 2p

Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.

Autor: Komrokji RS; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Lanino L; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy., Ball S; Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center and Vanderbilt University School of Medicine, Nashville, TN, USA., Bewersdorf JP; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Marchetti M; Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Maggioni G; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy., Travaglino E; IRCCS Polilcinico San Matteo, Pavia, Italy., Al Ali NH; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Fenaux P; Saint Louis Hospital, Paris Cité University, Paris, France., Platzbecker U; University Hospital Leipzig, Leipzig, Germany., Santini V; University of Florence, Florence, Italy., Diez-Campelo M; Haematology Department, University Hospital Salamanca, Salamanca, Spain., Singh A; Cleveland Clinic, Cleveland, OH, USA., Jain AG; Cleveland Clinic, Cleveland, OH, USA., Aguirre LE; Dana Farber Cancer Institute, Boston, MA, USA., Tinsley-Vance SM; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Schwabkey ZI; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Chan O; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Xie Z; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Brunner AM; Dana Farber Cancer Institute, Boston, MA, USA., Kuykendall AT; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Bennett JM; University of Rochester Medical Center, Rochester, NY, USA., Buckstein R; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Bejar R; University of California San Diego, San Diego, CA, USA., Carraway HE; Cleveland Clinic, Cleveland, OH, USA., DeZern AE; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA., Griffiths EA; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Halene S; Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., Hasserjian RP; Massachusetts General Hospital, Boston, MA, USA., Lancet J; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., List AF; Precision BioSciences, Durham, NC, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Odenike O; Leukemia Program, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, IL, USA., Padron E; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Patnaik MM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA., Roboz GJ; New York-Presbyterian/Weill Cornell Medicine, New York, NY, USA., Stahl M; Dana Farber Cancer Institute, Boston, MA, USA., Sekeres MA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Steensma DP; Ajax Therapeutics, Cambridge, MA, USA., Savona MR; Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center and Vanderbilt University School of Medicine, Nashville, TN, USA., Taylor J; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Xu ML; Department of Pathology and Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA., Sweet K; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Sallman DA; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Nimer SD; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Hourigan CS; Virginia Tech FBRI Cancer Research Center, Washington, DC, USA., Wei AH; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Sauta E; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy., D'Amico S; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Train, Milan, Italy., Asti G; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy., Castellani G; Department of Medical and Surgical Sciences-DIMEC, University of Bologna, Bologna, Italy., Delleani M; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy., Campagna A; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy., Borate UM; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA., Sanz G; Instituto de Salud Carlos III, Valencia, Spain., Efficace F; Department of Haematology, La Fe University and Polytechnic Hospital, Valencia, Spain., Gore SD; Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA., Kim TK; Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center and Vanderbilt University School of Medicine, Nashville, TN, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rozman M; Hospital Clínic Barcelona, Barcelona, Spain., Orfao A; Haematology Department, University Hospital Salamanca, Salamanca, Spain., Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Foucar MK; University of New Mexico, Albuquerque, NM, USA., Germing U; Department of Haematology, Oncology, and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany., Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany., Scheinberg P; Beneficência Portuguesa de São Paulo Hospital, São Paulo, Brazil., Miyazaki Y; Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan., Iastrebner M; Sanatorio Sagrado Corazón, Buenos Aires, Argentina., Kulasekararaj A; King's College Hospital NHS Foundation Trust, NIHR/Wellcome King's Clinical Research Facility, London, UK., Cluzeau T; Nice University Hospital, Nice, France., Kordasti S; Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College, London, UK., van de Loosdrecht AA; Department of Hematology, Amsterdam University Medical Center, VU University Medical Center-Cancer Center, Amsterdam, Netherlands., Ades L; Saint Louis Hospital, Paris Cité University, Paris, France., Zeidan AM; Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., Della Porta MG; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy. Electronic address: matteo.della_porta@hunimed.eu.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2024 Nov; Vol. 11 (11), pp. e862-e872. Date of Electronic Publication: 2024 Oct 09.

Clinical and molecular characteristics of extramedullary acute myeloid leukemias.

Autor: Kewan T; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.; Department of Hematology and Oncology, Yale University, New Haven, CT, USA., Bahaj WS; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Gurnari C; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy., Ogbue OD; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Mukherjee S; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Advani A; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Cook JR; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA., Rogers HJ; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA., Carraway HE; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Balasubramanian SK; Department of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA., Visconte V; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Maciejewski JP; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.

Publikováno v: Leukemia [Leukemia] 2024 Sep; Vol. 38 (9), pp. 2032-2036. Date of Electronic Publication: 2024 Jul 18.

Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations.

Autor: Gordon J; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Bravo-Perez C; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.; Department of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, University of Murcia, IMIB-Pascual Parrilla, CIBERER - Instituto de Salud Carlos III, Murcia, Spain., Guarnera L; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy., Unlu S; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Kawashima N; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Ahmed A; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Haddad C; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Kubota Y; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Nautiyal I; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Ullah F; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Dima D; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Williams ND; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Kewan T; Department of Hematology and Medical Oncology, Yale University, New Haven, CT, USA., Bahaj W; Division of Medical Oncology & Hematology, School of Medicine University of Louisville, Louisville, KY, USA., Carraway HE; Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Yang CY; Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA., Gurnari C; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy., Visconte V; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Maciejewski JP; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.

Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Jul 30; Vol. 14 (1), pp. 125. Date of Electronic Publication: 2024 Jul 30.